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Alzheimer’s disease (AD), the most common form of dementia, is characterized by the 
progressive loss of neurons and synapses, and by extracellular deposits of amyloid-β (A ) as 
senile plaques, A  deposits in the cerebral blood vessels, and intracellular inclusions of 
hyperphosphorylated tau in the form of neurofibrillary tangles. Several mechanisms 
contribute to AD development and progression, and increasing epidemiological and molecular 
evidence suggests a key role of cholesterol in its initiation and progression. Altered cholesterol 
metabolism and hypercholesterolemia appear to play fundamental roles in amyloid plaque 
formation and tau hyperphosphorylation. Over the last decade, growing evidence supports 
the idea that cholesterol oxidation products, known as oxysterols, may be the missing link 
between altered brain cholesterol metabolism and AD pathogenesis, as their involvement in 
neurotoxicity, mainly by interacting with Aβ peptides, is reported. 
 Alzheimer’s disease (AD), a neurodegenerative disorder, is the most common form of dementia in 
developed countries. It is a complex and genetically heterogeneous disease, characterized by 
progressive memory deficit, cognitive impairment and personality changes, accompanied by 
specific structural abnormalities in the brain. The main histological features of AD are extracellular 
deposits of amyloid-β (A ) in the form of senile plaques, A  deposits in the cerebral blood vessels, 
and intracellular inclusions of hyperphosphorylated tau in the form of neurofibrillary tangles (NFT). 
The loss of neurons and synapses in the neocortex, hippocampus and other subcortical regions of 
the brain is also a common feature of AD.
1,2
  
AD begins with the abnormal processing of amyloid precursor protein (APP) by the 
sequential enzymatic actions of two enzymes of the amyloidogenic pathway: beta-site amyloid 
precursor protein-cleaving enzyme 1 (BACE1), a -secretase, and -secretase; these actions lead to 
excess of production and/or reduced clearance of A  peptides, which comprise 39-43 amino acids. 
An imbalance between production and clearance of A  in the brain, and their aggregation, causes 
A  to accumulate, and this excess may be the initiating factor in AD. Monomers of A 40 are usually 
much more prevalent than the aggregation-prone and damaging A 42 species, but an increased 
proportion of A 42 appears sufficient to cause early onset of AD. Additionally, insoluble oligomers 
and intermediate amyloids are the most neurotoxic forms of A 42.
3
 
Several mechanisms (e.g. perturbation of brain metabolism, oxidative stress, inflammation, 
presence of the apolipoprotein E (ApoE) 4 allele, impaired cholesterol metabolism) contribute to 
the development and progression of AD. Among these, a growing body of epidemiological and 
molecular evidence suggests a mechanistic link between cholesterol and AD progression. A number 
of genes involved in cholesterol homeostasis have been identified as susceptibility loci for sporadic 
or late-onset AD,
4-6
 and altered cholesterol metabolism seems to play a fundamental role in the 
formation of amyloid plaques and in tau hyperphosphorylation.
7,8
 In addition, hypercholesterolemia 
is unanimously recognized to be a risk factor for sporadic AD, a form that accounts for the great 
majority of cases.
4,9-11
 Finally, this evidence is supported by epidemiological studies indicating that 
cholesterol-lowering agents belonging to the family of statins reduce the prevalence of AD,
12-14
 a 
conclusion not yet fully accepted because of the contradictory results reported by prospective 
clinical studies.
15-17
 
 
Apolipoprotein E and its receptors in AD 
 
ApoE is the brain’s principal cholesterol-carrier protein, mainly transporting it from astrocytes to 
neurons. The association between ApoE polymorphism and AD is presumably related to the 
disturbance of cholesterol transport. Of note, subjects who are homozygous for the ApoE 4 
genotype express an increased AD risk, versus those carrying 2 or 3, evidence that is consistently 
confirmed by numerous independent studies.
18-21
 In addition, receptors recognizing ApoE are also 
widely expressed in the AD brain.
4,20,22
  
Although ApoE mediates A  clearance by binding A  and forming a stable complex, ApoE 
may also stimulate Aβ aggregation and amyloid deposition, as well as tau hypersphorylation.20,22-25 
Moreover, among the mechanisms that might explain the effects of ApoE on the brain of AD 
subjects, ApoE 4 and its receptors are also reported to be involved in APP trafficking and its 
processing to A . Additionally, ApoE may mediate A  cell internalization, by binding to the LDL 
receptor-related protein (LRP).
26
 ApoE might also modulate the distribution and metabolism of 
cholesterol in neuronal membranes, and regulate the role of cholesterol in synapse formation and 
function, through ApoE receptors.
20,25,27
 Moreover, -secretase cleavage of APP could thus regulate 
ApoE metabolism through the LRP1 receptor.
27
 
A number of epidemiological studies also report that individuals with high levels of blood 
cholesterol have an increased susceptibility to AD, apparently influenced by the ApoE 4 genotype, 
which may influence cholesterol metabolism and the formation of cholesterol oxidation products, 
known as oxysterols.
28
  
 
Role of cholesterol in AD 
 
The brain is the organ with the highest concentration of cholesterol, which is essential for its normal 
function, being a major component of neuronal cell membranes and a determinant of membrane 
fluidity.
29
 In the brain, cholesterol is mostly present in the free form and is derived from de novo 
biosynthesis from acetyl-coenzyme A mediated by 3-hydroxy-3-methyl-glutaryl-coenzyme A 
(HMG-CoA) reductase, rather than from plasma lipoproteins, which are prevented by the blood-
brain barrier (BBB) from crossing from the peripheral circulation into the brain. Further, the 
astrocytic compartment meets neuronal cholesterol demands by secreting ApoE-cholesterol 
complexes, which are transported to the neurons.
30,31
 
The mechanism by which cholesterol affects A  production and metabolism is not fully 
understood; however, a change in membrane properties has been suggested.
9
 Cholesterol is mainly 
concentrated in membrane microdomains termed “lipid rafts”, where considerable evidence 
indicates that the amyloidogenic pathway takes place.
32,33
 In this connection, it has been reported 
that cellular cholesterol, especially when it is elevated in the membrane, binds directly to APP and 
thus promotes APP’s insertion into the phospholipid monolayers of the “lipid rafts” and other 
organelles where - and -secretases reside, and favors the amyloidogenic pathway.
34-36
 
Amyloidogenic activity is thus linked to cholesterol levels: - and -secretase activities are 
positively regulated by high and inhibited by low levels of cholesterol.
37,38
 Since APP processing 
and A  generation are associated with cholesterol-rich microdomains, and both are present in “lipid 
rafts”, A  production may require raft integrity and a lipid component as optimal conditions. An 
alteration in raft components could thus change the configuration of either the enzymes or the 
substrate associated with the rafts, leading to an alteration in A  generation. Conversely, in the non-
amyloidogenic pathway, APP is processed by -secretase in non-raft domains, and this event is 
promoted by a decreased cellular cholesterol level.
39
 Moreover, the amyloidogenic pathway is 
inactivated when -secretase is forced to associate with “lipid rafts”.40 
Cholesterol also enhances A  to form neurotoxic aggregates.
41
 In addition, fibrillogenesis of 
A  has been proposed to take place in “lipid rafts” at ganglioside clusters, where A  displays a 
specific affinity to cholesterol which binds avidly to A  protofibrils.
 42,43
 Moreover, it has been 
shown that increased cholesterol levels in the lipid bilayers facilitate binding of A  to the 
membranes, promoting A  conformational change from a helix-rich to a -sheet-rich structure, and 
thus becoming an endogenous seed for amyloid formation.
44
 The conversion of soluble and 
nontoxic monomeric A  to insoluble and toxic oligomeric and aggregate A  is thus the critical step 
in AD development.  
Given the above considerations, it seems that cholesterol distribution and trafficking within 
brain cells, rather than total cholesterol levels in the neurons, are the relevant factors in the APP 
processing  and A  accumulation in the AD progression.
45
   
It has also been observed that high concentrations of free cholesterol alone do not affect 
APP processing or A  production; rather, the conversion of excess free cholesterol into cholesterol 
ester has a profound effect on APP and A  enhancing their upregulation.
46
 Consequently, clearance 
of A  from the brain is reduced when an overabundance of esterified cholesterol decreases 
membrane lipid turnover. Conversely, inhibition of the enzyme acyl-coenzyme A:cholesterol acyl-
transferase 1 (ACAT1), which esterifies cholesterol, leads to the reduction of both cholesteryl esters 
and A .
47
 These data suggest that the balance between free cholesterol and cholesterol esters is a 
key parameter controlling amyloidogenesis, although the molecular mechanisms underlying this 
relationship are still unclear.  
A regulatory role for APP and -secretase in cholesterol metabolism, jointly acting to lower 
cellular cholesterol levels, has also been reported.
27 
The effect of A  and of the intracellular domain 
of APP (AICD) on cellular cholesterol metabolism have also been investigated.
 
A , in particular the 
oligomeric rather than the monomeric form, alters intracellular trafficking and cholesterol 
homeostasis, by promoting the release of cholesterol and some other lipids from cells, in the form of 
A -lipid particles.
48
 The fibrillar A  then down-regulates cholesterol biosynthesis.
49
 The AICD, 
which is released upon -secretase cleavage of APP, down-regulates cellular cholesterol uptake by 
acting as a transcriptional suppressor of LRP1 gene, a major ApoE receptor in the brain.
27
 
Furthermore, the peptide products of the amyloidogenic pathway ultimately reduce both cholesterol 
uptake and its biosynthesis, completing a negative feedback loop. A decrease in cellular cholesterol 
levels then results in an enhancement of tau phosphorylation
50
 and synaptic failure.
51
 It has also 
been demonstrated that extracellular cholesterol accumulates in the senile plaques and 
neurofibrillary tangles of AD patients, and in transgenic mice expressing the Swedish Alzheimer 
mutation APP751, as well as ApoE, and that cholesterol, ApoE and A  all colocalize in the core of 
fibrillar plaques.
52,53
 This shows that both ApoE and cholesterol may be essential for plaque 
formation, and that extracellular cholesterol, by binding to aggregated A , may be the seed for its 
deposition.  
 
Role of oxysterols in AD  
 
Because there is little synthesis of cholesterol in the adult brain, and because the brain cannot 
degrade cholesterol, it must be excreted from the brain in order to prevent its accumulation. The 
most important mechanism whereby the brain eliminates excess cholesterol is through the formation 
and excretion into the circulation of oxysterols, a class of cholesterol oxidation products, which are 
thus important to balance the local synthesis of sterols.
54
 
Cholesterol is primarily converted into the oxysterol 24-hydroxycholesterol (24-OH), also 
known as cerebrosterol, which is produced almost exclusively in the brain by CYP46A1 
(cholesterol 24-hydroxylase) and which, unlike cholesterol itself, can easily cross the BBB.
9,30,54,55
 
Following its secretion from the brain, 24-OH enters the circulation and reaches the liver, where it 
is taken up and metabolized. The oxysterol 24-OH also plays an important role in the regulation of 
cholesterol homeostasis in the brain. Neuronal cells have a lower rate of cholesterol synthesis than 
glial cells; for this reason, an increased flux of 24-OH from neurons to glial cells causes an 
increased flux of cholesterol to the neuronal cells, by means of activation of the nuclear liver X 
receptor (LXR) and upregulation of ApoE in the glial cells (Fig. 1).
56
 Another oxysterol, 27-
hydroxycholesterol (27-OH), has been found to be produced in situ in the brain by CYP27A1, 
although in small amounts, and then metabolized by the enzyme CYP7B to 7 -hydroxy-3-oxo-4-
cholestenoic acid (7-OH-4-C), which, crossing the BBB, reaches the liver where it is 
eliminated.
54,55,57
 However, it has been observed that most 27-OH flows from the circulation into 
the brain, since, unlike cholesterol, it can cross the BBB.
58
 Summarizing, these considerations 
indicate that there are fluxes of oxysterols in opposite directions across the BBB: two fluxes out of 
the brain (24-OH and 7-OH-4-C) and one flux into the brain (27-OH). A further compound, 7 -
hydroxycholesterol (7 -OH), may also derive in the brain from oxidation of cholesterol following 
cholesterol interaction with A  and APP (Fig. 2).
59
 
During the last decade, the idea that oxysterols might be the missing link between altered 
brain cholesterol metabolism and AD pathogenesis has been increasingly supported by research 
pointing to the involvement of 24-OH and 27-OH in neurotoxicity, mainly by interacting with Aβ 
peptides. 
Several studies have found higher levels of 24-OH in the peripheral circulation and 
cerebrospinal fluid (CSF) of AD patients during the early stages than in unaffected individuals, 
suggesting that cholesterol turnover in the brain increases during the neurodegenerative changes of 
AD.
60-62
 Conversely, plasma levels of 24-OH were decreased in patients with later stages of AD 
than in the respective controls, suggesting that the rate of cholesterol transport lowers as the disease 
progresses.
62,63 
These contradictory results might be rationalized by considering that increased 
plasma levels of 24-OH reflect ongoing neurodegeneration and/or demyelinization, whereas 
decreased plasma levels reflect a selective loss of neurons expressing CYP46A1.
30
 However, in 
glial cells of AD brains there is some ectopic induction of CYP46A1, and consequently some 24-
OH production, which may overlap with decreased neuronal expression in the presence of increased 
glial expression,
64,65
 although this induction of CYP46A1 cannot compensate for the loss of 24-
hydroxylase activity due to the neuronal degeneration. Another study, however, has found that 
plasma levels of 24-OH in AD patients are not significantly different than in control subjects.
66
 
It has also been reported that, in all brain areas of deceased AD patients, as well as in aged 
mice expressing the Swedish Alzheimer mutation APP751, the amount of 24-OH decreases and 27-
OH increases.
67
 A marked accumulation of 27-OH was also found in the brain of patients carrying 
the Swedish APP 670/671 mutation.
68
 Whereas the decreased levels of 24-OH in the AD brain are 
presumably due to the loss of neuronal cells and consequent loss of the enzyme CYP46A1, the 
increased levels of 27-OH may be due to increased flux of this oxysterol across the BBB, because 
of hypercholesterolemia
69
 or a damage of BBB integrity.
70
 An alternative explanation for the high 
levels of 27-OH is a reduced metabolism of the oxysterol into 7-OH-4-C, by the enzyme CYP7B, 
which is reduced in the brain of AD patients.
71
 However, increased levels of both 24-OH and 27-
OH have been observed in the CSF in patients with advanced AD.
72
 
From these considerations, the hypothesis has been formulated that the balance between 24-
OH and 27-OH is important for amyloidogenesis,
54,69
 and the increased ratio of 27-OH to 24-OH in 
AD brains is consistent with this hypothesis.
67
 Thus, the shift in balance between the two oxysterols 
might lead to increased generation and accumulation of A  and regulation of the 24-OH/27-OH 
ratio could be an important strategy in controlling A  levels in AD. However, opinions still differ 
about the involvement of these two oxysterols in the APP processing and A  generation. 
According to several studies, induction of CYP46A1 activity has beneficial effects, directly 
preventing A  generation by modulating cholesterol homeostasis and reducing cellular cholesterol. 
Indeed, astrocytes are sensitive to 24-OH-mediated upregulation of the LXR-responsive genes 
involved in cholesterol efflux, i.e. ATP-binding cassette transporter A1 and G1 (ABCA1 and 
ABCG1) and ApoE.
56
 Conversely, the low levels of 27-OH in the brain might also be expected not 
to affect amyloidogenesis. However, since the flux of 27-OH across the BBB increases under 
conditions of hypercholesterolemia,
69
 or in the case of reduced BBB integrity,
70
 the inhibitory effect 
of 24-OH on A  generation is consequently reduced. In this connection, the high flux of 27-OH 
from the peripheral circulation to the brain, and changes in the brain cholesterol/oxysterol balance, 
may partially explain the link between hypercholesterolemia and AD.
69
 Nevertheless, in murine 
primary neuronal cells both 24-OH and 27-OH were found to inhibit A  formation and secretion, 
24-OH being about 1000-fold more potent than 27-OH.
65
 The study showed that the distribution of 
the enzymes CYP46A1 and CYP27A1 is altered in the brain of subjects with AD. CYP46A1, 
whose expression increases in astrocytes and decreases in neurons, is selectively expressed in 
degenerating neuritis around senile plaques, whereas CYP27A1 expression, which is mostly 
expressed in neurons but also to a lesser extent in astrocytes and oligodendrocytes, is increased in 
white-matter oligodendrocytes.
65
 Moreover, it has been shown that 27-OH significantly reduces A  
peptide generation from primary human neurons, not by affecting -, -, or -secretase but by 
upregulating LXR responsive genes (ABCA1, ABCG1 and ApoE).
73
 Of note the LXR-mediated 
gene regulation of cholesterol efflux and metabolism not only modulates neurodegeneration and A  
peptide transport and clearance but also inflammation in the brain. On the basis of these data it 
cannot be excluded that 27-OH, as an LXR ligand, might exert anti-amyloidogenic effects by 
reducing extracellular A  and inflammation.
74-77
 
By contrast, other studies are consistent with the possibility that 27-OH may accelerate 
neurodegeneration. In human SH-SY5Y neuroblastoma cells, 24-OH directly increases -secretase 
activity as well as elevating the /  activity ratio, whereas 27-OH counteracts the inhibitory effect 
of 24-OH on the generation of amyloid.
78
 In addition, recent studies underlined the different effects 
of 24-OH and 27-OH on APP levels and processing in human neuroblastoma SH-SY5Y cells and in 
the brain tissue: 24-OH may favor the non-amyloidogenic pathway, whereas 27-OH is thought to 
enhance production of A 42 by upregulating APP and BACE1, and tau hyperphosphorylation.
79,80
 
Another study has found that 27-OH increases A  accumulation by reducing insulin-like growth 
factor 1 (IGF1) levels, a neurotrophic factor that promotes neurogenesis and has a neuroprotective 
effect, in hippocampal slices from adult rabbits;
81
 in addition, 27-OH reduces the production of the 
“memory protein” activity-regulated cytoskeleton-associated protein (Arc) in mouse brain.82 
Alongside altered cholesterol metabolism and hypercholesterolemia, inflammatory response 
and oxidative stress also significantly contribute to neuronal damage in AD.
83,84  
The importance of inflammatory processes has been pointed out during the past decade by 
the intensive investigation of inflammatory mediators and microglia activation in the brain of AD, 
although it remains unclear whether inflammation represents a cause or a consequence of AD. It has 
been reported that intraneuronal A  and soluble A  oligomers activate microglia in the earliest 
stages of the disease, even before plaque and tangle formation, in particular when cells are 
stressed.
85-87
 Fibrillar A  also can activate microglia by binding to cells via specific receptors, in 
particular through a multireceptor complex involving CD36, 6 1-integrin and CD47.
88
 The 
induction of a microglia-driven inflammatory response results in the release of various 
inflammatory mediators, including a whole array of neurotoxic cytokines and free radicals.
89
 Once 
activated, microglia cells may also recruit astrocytes, which actively enhance the inflammatory 
response to extracellular A  deposits that intensify neuronal dysfunction and cell death: 
inflammatory mediators and other components of the immune system are often found near areas of 
amyloid plaques.
90
 
It has also been postulated that oxidative stress may be either a cause or a consequence of 
the neuropathology associated with AD
91-94
 and, in support of its being a consequence, A  can 
stimulate the production of reactive oxygen species (ROS).
95
 Conversely, oxidative stress has been 
shown to contribute to the formation of amyloid plaques,
96
 since A  peptide has been found in the 
oxidized form.
97
 Since the brain has a high lipid content, it is extremely vulnerable to free radicals 
and ROS, which are responsible for enhancing lipid peroxidation, including cholesterol oxidation 
and oxysterol formation
98
 as well as tau hyperphosphorylation and NFT formation,
99 
mitochondrial 
insufficiency and neuronal cell death.
100
 
Oxysterols have been shown to enhance A  aggregation and its neurotoxicity, by modifying 
specific sites of A  peptide. Following A  modification at Lys-16, peptide aggregates were formed 
faster than in the case of modification at Lys-28 or Asp-1.
101
 Moreover, 7 -OH has been found to 
be neurotoxic at nanomolar concentrations in cultured rat hippocampal neuronal cells, and may 
therefore contribute to A -related neurodegeneration in the brain of AD patients.
59
 Another 
oxysterol that might derive from the autooxidation of cellular cholesterol released during 
neurodegeneration, is 7 -hydroperoxycholesterol, which has also been found to be responsible for 
necrotic cell death of SH-SY5Y cells,
102
 and a further possibility is 7-ketocholesterol.
103
 
Additionally, 24-OH has been shown to enhance the neurotoxic effect of the A 42 peptide in the 
human differentiated neuroblastoma cell line MSN, as well as augmenting ROS generation.
104
 
In our recent study, we examined the ways in which the oxysterols 24-OH, 27-OH, and 7 -
OH, specifically implicated in brain pathophysiology, may modulate and possibly amplify the 
expression of AD.
105
 All three oxysterols strongly enhanced the binding and concentration of A 42 
on membranes of human differentiated neuronal cell lines (SK-N-BE and NT-2) by markedly 
upregulating expression and synthesis of CD36 and 1-integrin receptors, two components of the 
multireceptor complex CD36/ 1-integrin/CD47, through which A  peptide binds to membrane 
cells.
88
 An interesting finding of the same study is that only 24-OH significantly potentiates both 
the necrogenic and the apoptotic effects exerted by A 42 peptide on these cells (Fig. 3A and B). 
These effects were inhibited when 24-OH-treated neuronal cells were incubated with anti-CD36 and 
anti- 1-integrin antibodies before A 42 addition, since A  peptide binding to the cell surface was 
prevented. One significant reason for this selective behavior of 24-OH appears to be its marked pro-
oxidant action on neuronal cells, by locally increasing ROS generation, an action not exerted by 
either 27-OH or 7 -OH (Fig. 3C). The 24-OH-dependent potentiation of A  neurotoxicity was 
completely inhibited by incubation of differentiated SK-N-BE or NT-2 cells with either the flavonol 
quercetin or the isoflavone genistein.
105
  
However, despite the present knowledge demonstrates that cholesterol and some oxystetrols 
play a key role in the AD pathogenesis interacting with A  (Fig. 4), elucidation of the precise 
mechanisms will clearly require further study. 
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Figure legends 
Figure 1. Cholesterol homeostasis in the mature brain. Excess cholesterol is converted into 24-
hydroxycholesterol (24-OH) in neuronal cells by CYP46A1. Most of the 24-OH goes directly from 
the brain into the blood circulation, a small quantity entering the cerebrospinal fluid (CSF). 24-OH 
may also be caught by astrocytes, where it upregulates the nuclear receptor liver X receptor (LXR)-
responsive genes involved in cholesterol efflux, i.e. ATP-binding cassette transporter A1 and G1 
(ABCA1 and ABCG1) and apolipoprotein E (ApoE). Synthesized cholesterol is loaded by 
astrocytes onto ApoE, and the ApoE/cholesterol complex is then internalized by neurons via low-
density lipoprotein receptors (LDLR). 
Figure 2. Fluxes of 24-hydroxycholesterol (24-OH) and 27-hydroxycholesterol (27-OH) through 
the blood brain barrier (BBB). The enzymes CYP46A1 and CYP27A1, located in the neuronal 
cells, are respectively responsible for generating 24-OH and 27-OH in the brain. However, most of 
the 27-OH flows from the circulation into the brain since, unlike cholesterol, it can cross the BBB, 
as can 24-OH. In the brain, 27-OH is also metabolized to 7 -hydroxy-3-oxo-4-cholestenoic acid (7-
OH-4-C), which crosses the BBB to reach the liver. In conclusion, there is a complex of fluxes of 
oxysterols in opposite directions at the BBB: two fluxes out of the brain (24-OH and 7-OH-4-C) 
and one flux into the brain (27-OH). Of note, the shift in balance between 24-OH and 27-OH is 
important for amyloidogenesis since it might lead to increased generation and accumulation of A  
in AD brain. 
Figure 3. (A) Necrotic effects of 27-hydroxycholesterol (27-OH), 7β-hydroxycholesterol (7β-OH), 
or 24-hydroxycholesterol (24-OH) evaluated in terms of lactate dehydrogenase (LDH) release. SK-
N-BE cells were treated with the oxysterol (1 µM) for 48 h, and then for 24 h with Aβ42 (1 µM). 
Histograms represent the mean values ± SD of 3 experiments. **P < 0.01 vs. control (untreated 
cells). (B) Apoptotic effects of 27-OH, 7β-OH, or 24-OH on SK-N-BE cells observed by DAPI 
staining to determine apoptotic nuclei formation. Cells were treated with the oxysterol for 48 h and 
then for 24 h with Aβ42. (C) Pro-oxidant effects of 27-OH, 7β-OH, or 24-OH. Intracellular 
generation of reactive oxygen species (ROS) was examined in SK-N-BE cells using 2’,7'-
dichlorodihydrofluorescein (DCFH-DA) as an intracellular probe. Cells were incubated with 
oxysterol for 1 h, or simultaneously with oxysterol plus Aβ42 for 1 h. 
Figure 4. Interaction between lipid metabolism and amyloid-  (A ) processing. The major source 
of cerebral cholesterol is de novo synthesis from acetyl-coenzyme A mediated by 3-hydroxy-3-
methyl-glutaryl-coenzyme A (HMG-CoA) reductase. Excess cholesterol is converted into 
cholesteryl esters by acyl-coenzyme A:cholesterol acyl-transferase (ACAT) and into the oxysterols 
24- and 27-hydroxycholesterol (24-OH, 27-OH) by CYP47A1 and CYP27A1, respectively; the 
oxysterol 7 -hydroxycholesterol (7 -OH) may derives from cholesterol oxidation by A  and 
amyloid protein precursor (APP). A  production is increased  by  HMG-CoA reductase and ACAT 
activity and by cholesterol which regulates - and  -secretase. LDL receptor-related protein (LRP) 
mediates the internalization of astrocyte-produced ApoE-cholesterol complexes into neurons. The 
intracellular domain of APP down-regulates cellular cholesterol uptake by acting as a 
transcriptional suppressor of LRP1 gene. 24-OH and 27-OH upregulate ATP-binding cassette 
transporter A1 (ABCA1), involved in cholesterol efflux, which modulates A  levels in neurons; 
these oxysterols increase ApoE levels and induce A  aggregation which  is also promoted by free 
ApoE and cholesterol. 
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